Journal of Antimicrobial Chemotherapy

Article	Citations
Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient	116
Point-of-care tests to manage acute respiratory tract infections in primary care: a systematic review and qualitative synthesis of healthcare professional and patient views	90
Prosthetic joint infections: 6 weeks of oral antibiotics results in a low failure rate	82
A drug candidate for Alzheimer’s and Huntington’s disease, PBT2, can be repurposed to render Neisseria gonorrhoeae susceptible to natural cationic antimicrobial peptides	74
Correction to: Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomon	67
Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR)	58
Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching—authors’ response	58
Low rates of complications and β-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy	55
Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan	52
Off-label use of dalbavancin in children: a case series	52
Specific mutations in the HIV-1 G-tract of the 3′-polypurine tract cause resistance to integrase strand transfer inhibitors	49
Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection	48
Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis	46
Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study	44
Mitigation of benznidazole toxicity and oxidative stress following ascorbic acid supplementation in an adult traveller with chronic indeterminate Chagas’ disease	44
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches	43
Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019	43
The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study	41
Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels	40
Evaluation of the RESIST ACINETO multiplex immunochromatographic assay for detection of OXA-23-like, OXA-40/58-like and NDM carbapenemase production in Acinetobacter baumannii	40
NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina	40
Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudom	38
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark	38
Precision dosing of vancomycin: in defence of AUC-guided therapy in children	37
General practice antibiotic prescriptions attributable to respiratory syncytial virus by age and antibiotic class: an ecological analysis of the English population	36

Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance	36
Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir	36
Genomic analyses of Staphylococcus aureus isolated from yaks in Ganzi Tibetan Autonomous Prefecture, China	36
Comment on: A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	35
Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?	35
Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence	34
Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in vivo	34
Correction to: Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species	34
SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase	34
A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis	33
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study	33
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus	33
Transmission barrier of the blaKPC plasmid mediated by type I restriction-modification systems in Escherichia coli	33
Engineering a CRISPR interference system targeting AcrAB-TolC efflux pump to prevent multidrug resistance development in Escherichia coli	32
Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations	32
Development and application of Cas13a-based diagnostic assay forNeisseria gonorrhoeaedetection and azithromycin resistance identification	31
Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence ofClostridioides difficileinfection: a propensity score analysis	31
Inhibition of d-alanylation of teichoic acids overcomes resistance of methicillin-resistant Staphylococcus aureus	31
Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells	31
Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco	31
Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France	30
Synergistic effects of quorum-sensing molecules and antimicrobials against Candida albicans and Pseudomonas aeruginosa biofilms: in vitro and in vivo studies	28
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2	28
Correction to: Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	28
Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK	28
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads	28
Activity of mecillinam against carbapenem-resistant Enterobacterales	26
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!—authors’ response	26
Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a	26
Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home–acquired urinary tract infections	26
A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa	26
Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial	26
Antibiotic biocompatibility assay and anti-biofilm strategies for Pseudomonas aeruginosa infection in bioengineered artificial skin substitutes	26
Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a mul	25
External quality assurance (EQA) network in South and South-East Asia: experience and results from an international EQA programme in One Health sector reference laboratories	25
Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases	25
In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model	25
Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis—authors’ response	25
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap	24
Activity of fosfomycin/colistin combinations against planktonic and biofilm Gram-negative pathogens	24
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort	24
Redefining therapeutic success in HIV patients: an expert view	24
Effect of sigma E on carbapenem resistance in OXA-48-producing Klebsiella pneumoniae	24
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae	24
Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016–20	23
Antibiotic-induced degradation of antitoxin enhances the transcription of acetyltransferase-type toxin-antitoxin operon	23
Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022	23
Rifabutin versus rifampicin bactericidal and antibiofilm activities against clinical strains of Staphylococcus spp. isolated from bone and joint infections	23
Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) directly from positive blood culture bottles without the advanced identification systems	23
Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children	23

Reduced effectiveness among β-lactam antibiotics: a population-based cohort study in primary care in Italy	23
Influence of tedizolid on the cytokine response to the endotoxin challenge in healthy volunteers: a cross-over trial	23
Plasma concentration of orally administered amoxicillin and clindamycin in patients receiving haemodialysis	23
Comparison of different biomass methodologies to adjust sales data on veterinary antimicrobials in the USA	23
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre inf	23
Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates	23
Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates	22
Characterization of a multiresistance optrA- and lsa(E)-harbouring unconventional circularizable structure in Streptococcus suis	22
Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption	22
Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and	22
Selection and characterization of mutational resistance to aztreonam/avibactam in β-lactamase-producing Enterobacterales	22
Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study	22
Clinical characteristics and management of olecranon and prepatellar septic bursitis in a multicentre study	22
Pharmacokinetics and placental transfer of dolutegravir in pregnancy	22
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections	21
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?	21
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginos	21
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	21
Leveraging interdisciplinary management in people with HIV and lymphoid neoplasms	21
Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions	21
Genomic analysis reveals the population structure and antimicrobial resistance of avian Pasteurella multocida in China	21
Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants	21
Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review	20
Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway—an interrupted time series analysis	20
Reporting England’s progress towards the ambitions in the UK action plan for antimicrobial resistance: the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR)	20
Swedish multicentre study of target attainments with β-lactams in the ICU: which MIC parameter should be used?	20
Streptococcus suisprophage lysin as a new strategy for combating streptococci-induced mastitis andStreptococcus suisinfection	20
Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study	19
Validation of the Antifungal National Antimicrobial Prescribing Survey (AF-NAPS) quality assessment tool	19
Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-	19
Identification of multiple transfer units and novel subtypes of tmexCD-toprJ gene clusters in clinical carbapenem-resistant Enterobacter cloacae and Klebsiella oxytoca	19
In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study	19
Usefulness of inclusion of ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoni	19
Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin Americ	19
Dissemination of Klebsiella pneumoniae ST147 NDM-1 in Poland, 2015–19	19
SARS-CoV-2 coinfection with additional respiratory virus does not predict severe disease: a retrospective cohort study	19
Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients	19
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases	19
Evaluation of fidaxomicin use in patients with a macrolide allergy/intolerance	19
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine	19
Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia	19
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	18
Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes	18
Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences	18
Stability of temocillin in outpatient parenteral antimicrobial therapy: is it a real option?	18
The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies	18
Antibiotic use by clinical presentation across all healthcare providers in rural Burkina Faso: a healthcare visit exit survey	18
A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa	18
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and	18
Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from Uganda, Malawi and South Africa, 2015–20	18
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis	18
Temporal trends in antibiotic prescribing and serious and nonserious infections in children presenting to general practice: a registry-based longitudinal cohort study of 162 507 individuals	18
Interventions to improve antibiotic use among dentists: a systematic review and meta-analysis	18
Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa	17
Establishment of RCPA national guidelines for selective reporting of antimicrobials: processes, challenges and measuring the impact	17
Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis	17
Characterization of an MDR Lactobacillus salivarius isolate harbouring the phenicol-oxazolidinone-tetracycline resistance gene poxtA	17
Correction to: Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India	17
Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017	17
Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example	17
Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children	17
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections	17
Decreased cyclic-AMP caused by ATP contributes to fosfomycin heteroresistance in avian Escherichia coli	17
Antibiotic prescription policy for acute otitis media: do we follow the guidelines?	17
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs	17
Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis	17
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa	17
The acquisition of transferable extrachromosomal fec operon is associated with a cefiderocol MIC increase in Enterobacterales	17
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors	17
Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?	17
Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020	17
Impact of veterinary antibiotics on plasmid-encoded antibiotic resistance transfer	17
Diagnostic uncertainties in patients with bacteraemia: impact on antibiotic prescriptions and outcome	17
Subcutaneously administered antibiotics: a review (addendum)	17
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates	17
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	16
Acknowledgement of referees	16
Surveillance of antimicrobial resistant Shiga toxin-producing E. coli O157:H7 in England, 2016–2020	16
Pristinamycin-induced sideroblastic anaemia	16
Clinical aspects and recent advances in fungal diseases impacting human health	16

HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir	16
Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation	16
Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients	16
A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus	16
Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses	16
Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?—authors’ response	16
In vitro and in vivo antibacterial activity, resistance analysis and molecular docking study of pleuromutilin derivatives against Streptococcus suis	16
Relationship of TonB-dependent receptors with susceptibility to cefiderocol in clinical isolates of Pseudomonas aeruginosa	15
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients—authors’ response	15
Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial	15
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis	15
Identification of vancomycin exposure target in neonates: how much is enough?	15
Impact of changed co-amoxiclav susceptibility testing formats on apparent resistance rates for bloodstream Escherichia coli in a long-term surveillance	15
Preface	15
Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program	15
Diffusion of amoxicillin into heart valves from infective endocarditis patients	15
A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19	15
In vivo evaluation of cefazolin inoculum effect in the treatment of experimental Staphylococcus aureus pneumonia with cefazolin	15
Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales	15
Professor Alasdair Macintosh Geddes, 14 May 1934–9 April 2024	15
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)	15
Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’	15
The antiplasmodial activity of the carboxylic acid metabolite of piperaquine and its pharmacokinetic profiles in healthy volunteers	15
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114	15
Antifungal use in children with acute leukaemia: state of current evidence and directions for future research	15
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa	15
Cl415, a carbapenem-resistant Acinetobacter baumannii isolate containing four AbaR4 and a new variant of AbGRI2, represents a novel global clone 2 strain	15
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates	15
Refractory versus resistant invasive aspergillosis	15
Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections	15
Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea	15
Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023	15
Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials	15
Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia	15
Activity of rezafungin against Candida auris	14
Gastric acid suppression, lifestyle factors and intestinal carriage of ESBL and carbapenemase-producing Enterobacterales: a nationwide population-based study	14
A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models	14
In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species	14
Phenotypic and genetic characterization of antimicrobial resistance inSalmonella entericaserovar Choleraesuis isolates from humans and animals in Spain from 2006 to 2021	14
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/	14
Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU	14
The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study	14
Changing epidemiology of MRSA-CC398 in Spanish hospitals located in areas with different pig farming densities: a 2023 multicentre study	14
Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the	14
Carbapenem resistance in Enterobacterales bloodstream infections among children with cancer or post-haematopoietic stem cell transplant: a retrospective cohort study	14
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions	14
Genomic comparison of mecC-carrying methicillin-resistant Staphylococcus aureus from hedgehogs and humans in the Netherlands	14
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments	14
Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation ceph	14
JAC Supplement: ‘faster ID and AST revolution: how to improve antibiotic use in the critically ill’	14
Development and validation of a resazurin assay for in vitro susceptibility testing of Actinomadura madurae: a common causative agent of actinomycetoma	14
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial	14
Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010–19 period	14
Hospitalizations and severe complications following acute sinusitis in general practice: a registry-based cohort study	14
An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis	14
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa	14
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22	14
Correction to: Linezolid brain penetration in neurointensive care patients	14
PrEP monitoring and HIV incidence after PrEP initiation in France: 2016–18 nationwide cohort study	14
Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan	14
Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistantAcinetobacter baumanniiinfections	14
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting	14
HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H	14
Fluoroquinolones in orthopaedic infection: balancing risks and rewards	14
Emergence of mcr-8.1 gene coexisting with blaNDM in Citrobacter werkmanii isolated from a chicken farm in China	14
Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY)	14
Foreword	14
Efficacy of dihydroartemisinin/piperaquine in patients with non-complicated Plasmodium falciparum malaria in Yaoundé, Cameroon	14
Helicobacter pylori culture positivity and antimicrobial susceptibility profiles (Vancouver, Canada)	14
Broad-spectrum in vitro activity of macrophage infectivity potentiator inhibitors against Gram-negative bacteria and Leishmania major	14
Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study	14
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa	14
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and syndromic treatment of men with urethral discharge in Kingston, Jamaica, 2018–19	13
Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015–16 to 2020–21 seasons: from the VENUS study	13
Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding	13
Synergistic bactericidal activity of a novel dual β-lactam combination against methicillin-resistant Staphylococcus aureus	13
Evaluation of an optimized intermittent vancomycin dosing regimen in infants	13
Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool	13
Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections	13
Emergence of rare carbapenemases (FRI, GES-5, IMI, SFC and SFH-1) in Enterobacterales isolated from surface waters in Japan	13
Comment on: Clinical and serological outcomes in patients treated with oral doxycycline for early neurosyphilis	13
Pharmacokinetics of vaginally applied integrase inhibitors in macaques	13
Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volun	13
Genomic surveillance and antimicrobial resistance in Neisseria gonorrhoeae isolates in Bangkok, Thailand in 2018	13
Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates	13
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis	13
Ganciclovir therapeutic drug monitoring in transplant recipients	13
Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009–2020	13
Mitochondrial DNA mutations in HIV-exposed uninfected infants following the cessation of triple antiretroviral drugs	13
In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different Gyr	13
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study	13
Characterization of a cfr-bearing integrative and conjugative element in Proteus cibarius coharbouring tet(X6) on the chromosome	13
Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing ofPseudomonas aeruginosa	13
Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models	13
Utilizing dried blood spot micro-sampling and population pharmacokinetic modelling and simulation to inform ampicillin dosing in Chinese neonates	13